The European Union should renegotiate a 1 billion euro (US$1.2 billion) contract it sealed last week with Gilead for a six-month supply of the COVID-19 drug remdesivir after it showed poor results in a large trial, experts said on Friday.
EU urged to review remdesivir supply deal after COVID-19 trial results
